title: Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia.
abstract: OBJECTIVE
  The aim of this study was to evaluate the cost-effectiveness of alemtuzumab (CAMPATH-1H) compared with conventional chemotherapy in people with T-cell prolymphocytic leukemia (T-PLL).
  
  
  METHODS
  We developed a decision-analytic model to assess the costs and benefits of alemtuzumab or conventional therapy based on their effects on quality of life of patients. The main outcome was the incremental cost-effectiveness ratio incorporating costs per additional quality-adjusted life-year (QALY) gained over lifetime. Due to the limited data available, a large number of assumptions had to be made to construct the cost-utility model. One-way, multi-way, and probabilistic sensitivity analyses (PSA) were conducted to explore the impact of these uncertainties. Expected values of perfect information were also calculated for four specific scenarios.
  
  
  RESULTS
  Depending on different key assumptions made, the PSA suggested distinct conclusions using a willingness-to-pay threshold of 30,000 GBP per QALY gained. Using this threshold, the probability that alemtuzumab would be cost-effective varies from 0 percent to 53 percent for the four modeled scenarios. Population expected value of perfect information analysis suggests that resolving the parameter uncertainty in the analysis for people with T-PLL in the United Kingdom would have considerable value--up to 5.3 million euro.
  
  
  CONCLUSIONS
  Alemtuzumab appears more likely to be cost-effective if used earlier in the course of T-PLL and where it replaces the use of multiple alternative therapies. However, cost-effectiveness is highly uncertain and future research is clearly justified. Nevertheless, our analysis demonstrates the feasibility of considering the cost-effectiveness of an agent despite the presence of significant uncertainty to provide appropriate assessment information to policy makers.
authors.affiliation: Unviersity of Exeter, Exeter, United Kingdom. lulanting@gmail.com
authors.forename: Lanting
authors.initials: L
authors.lastname: Lu
authors.forename: Jaime
authors.initials: J
authors.lastname: Peters
authors.forename: Chris
authors.initials: C
authors.lastname: Roome
authors.forename: Ken
authors.initials: K
authors.lastname: Stein
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004739:England; D006801:Humans; D015461:Leukemia, Prolymphocytic, T-Cell / Q000188:drug therapy*; D008962:Models, Theoretical; D019057:Quality-Adjusted Life Years
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab